Table 1.
Representative Demographic and Clinical Characteristics of Included Patients
| Birmingham | Boston | Houston | Pittsburgh | Seattle | Overall | |
|---|---|---|---|---|---|---|
| Patients, n | 38 | 26 | 28 | 23 | 83 | 198 |
| Sampling period, yr, mean (SD) | 1.9 (0.1) | 1.8 (0.2) | 1.7 (0.3) | 1.8 (0.2) | 2.2 (1.3) | 2 (0.9) |
| Isolates per patient, mean (SD) | 5.2 (4.3) | 3.6 (2.6) | 4.2 (4) | 5.9 (4) | 7.1 (6.2) | 5.7 (5.1) |
| Age at enrollment, yr, mean (SD) | 11.7 (2.8) | 12.6 (3.1) | 12.1 (3.3) | 12 (3.1) | 9.3 (4) | 10.9 (3.7) |
| Sex, F, n (%) | 17 (44.7) | 11 (42.3) | 20 (71.4) | 15 (65.2) | 48 (57.8) | 111 (56.1) |
| Mutation type, n (%) | ||||||
| ΔF508 homozygote | 20 (52.6) | 13 (50) | 18 (64.3) | 14 (60.9) | 51 (62.2) | 116 (58.9) |
| ΔF508 heterozygote | 15 (39.5) | 13 (50) | 10 (35.7) | 6 (26.1) | 21 (25.6) | 65 (33) |
| Other | 3 (7.9) | 0 (0) | 0 (0) | 3 (13) | 10 (12.2) | 16 (8.1) |
| Any MRSA isolated during study period, n (%) | 27 (71.1) | 9 (34.6) | 12 (42.9) | 16 (69.6) | 30 (36.1) | 94 (47.5) |
| Any SCV S. aureus isolated during study period, n (%) | 12 (31.6) | 4 (15.4) | 3 (10.7) | 11 (47.8) | 27 (32.5) | 57 (28.8) |
| Chronic P. aeruginosa coinfection*, n (%) | 7 (18.4) | 4 (15.4) | 8 (28.6) | 3 (13) | 30 (36.1) | 52 (26.3) |
| Antibiotic exposure during study period (any), n (%) | ||||||
| Fluoroquinolone | 22 (57.9) | 10 (38.5) | 10 (35.7) | 10 (43.5) | 26 (31.3) | 78 (39.4) |
| Aminoglycoside | 29 (76.3) | 9 (34.6) | 13 (46.4) | 9 (39.1) | 35 (42.2) | 95 (48) |
| β-Lactam | 18 (47.4) | 21 (80.8) | 17 (60.7) | 19 (82.6) | 69 (83.1) | 144 (72.7) |
| Macrolide | 33 (86.8) | 8 (30.8) | 11 (39.3) | 8 (34.8) | 30 (36.1) | 90 (45.5) |
| Rifamycin | 1 (2.6) | 0 (0) | 1 (3.6) | 2 (8.7) | 11 (13.3) | 15 (7.6) |
| Tetracycline | 10 (26.3) | 5 (19.2) | 5 (17.9) | 2 (8.7) | 9 (10.8) | 31 (15.7) |
| TMP–SMX | 25 (65.8) | 9 (34.6) | 9 (32.1) | 8 (34.8) | 32 (38.6) | 83 (41.9) |
| FEV1% predicted, enrollment baseline, mean (SD) | 93.7 (18) | 99.6 (17) | 95.7 (15.3) | 94.2 (12.5) | 91.6 (21.2) | 94.1 (18.2) |
| FEV1% predicted, slope over study period (% predicted/yr), mean (SD) | 0.66 (4.1) | 0.61 (7.5) | −2.7 (4.9) | −5.26 (6) | −0.25 (6.2) | −0.89 (6.3) |
Definition of abbreviations: MRSA = methicillin-resistant S. aureus; P. aeruginosa = Pseudomonas aeruginosa; S. aureus = Staphylococcus aureus; SCV = small-colony variant; TMP-SMX = trimethoprim-sulfamethoxazole.
Complete clinical and demographic characteristics were available for 198 of 248 included patients.
*
P. aeruginosa isolated from majority of cultures obtained during study period.